µç»°¾Ù±¨£º0591-38265150
Óʼþ¾Ù±¨£ºcosunterjb@163.com
Ðżþ¾Ù±¨£º¸£½¨Ê¡¸£ÖݸßÐÂÇøÎÚÁú½ÖдóµÀ7ºÅÁ¢ÒìÔ°¶þÆÚ16ºÅÂ¥£¬ÓÊÕþ±àÂ룺350003£¬ÊÕ¼þÈË£º¼à²ìÈÏÕæÈË
רעÓÚ¿¹²¡¶¾ÖÎÁÆ¿ª·¢ºÍÊг¡»¯µÄÉúÎïÖÆÒ©¹«Ë¾ContraVir PharmaceuticalsÐû²¼ÁËÆäÔÚÑп¹ÒÒÐ͸ÎÑײ¡¶¾(HBV)ÐÂÒ©CMX157µÄÆð¾¢ÖÐÆÚÊý¾Ý£¬Õâ¸öÇ¿Ð§ÌæÅµ¸£Î¤( tenofovir)ǰҩ·Ö×ÓÏÖÔÚÕýÔÚ2aÆÚÁÙ´²Ñо¿ÖоÙÐжàÖØµÝÔö¼ÁÁ¿µÄÆÀ¹À¡£
ÒÒÐ͸ÎÑ×ÊÇÓÉÓÚHBV²¡¶¾Ôì³ÉµÄÒ»ÖÖË𺦸ÎÔàµÄ¼²²¡¡£¸Ã²¡¶¾Ñ¬È¾¿ÉÍþвÉúÃü£¬ÊÇÒ»¸öÑÏÖØµÄÈ«ÇòÎÀÉúÎÊÌâ¡£µ±HBV²¡¶¾Ôì³ÉÂýÐÔѬȾ£¬»¼Õ߾߸ßΣº¦ËÀÓÚ¸ÎÓ²»¯ºÍ¸Î°©¡£¾ÝÌìÏÂÎÀÉú×éÖ¯Ô¤¼Æ£¬È«ÇòÔ¼ÓÐ2.4ÒÚÈËÂýÐÔѬȾÒÒÐ͸ÎÑ×£¬Ã¿ÄêÓÐÁè¼Ý68.6ÍòÈËËÀÓÚÒÒÐ͸ÎÑײ¢·¢Ö¢(°üÀ¨¸ÎÓ²»¯ºÍ¸Î°©)¡£Õë¶ÔÂýÐÔÒҸοÉÒÔ¿Ú·þ¿¹²¡¶¾Ò©ÎïµÈÒ©Îï¾ÙÐÐÖÎÁÆ£¬ÑÓ»º¸ÎÓ²»¯Àú³Ì£¬½µµÍ¸Î°©·¢²¡ÂÊ£¬ÖÕÌá¸ß´æ»îÂÊ¡£
2015Äê3Ô£¬ÌìÏÂÎÀÉú×éÖ¯Ðû²¼ÁË·ÝÔ¤·À¡¢Õչ˻¤Ê¿ºÍÖÎÁÆÂýÐÔÒÒ¸ÎѬÎʶ¦ÄÏ£ºÆäÖн¨ÒéʹÓúËÜÕËáÀàËÆÎï¿Ú·þÒ©Î¡ªÌæÅµ¸£Î¤»ò¶÷Ìæ¿¨Î¤¡ª¡ª×÷ΪһÏߺͶþÏßÒ©ÎïʹÓá£ÕâÊÇÒ»ÀàÒÖÖÆHBV²¡¶¾µÄÓÐÓÃÒ©Î½ÏÉÙµ¼ÖÂÄÍÒ©ÐÔ£¬ÌìÌìһƬ£¬¸±×÷ÓúÜС¡£
ÉúÎïÖÆÒ©¹«Ë¾ContraVirÌØÊâ¹Ø×¢¿ª·¢Õë¶ÔHBV²¡¶¾µÄDZÔÚÁ¢ÒìÐÔÁÆ·¨¡£¸Ã¹«Ë¾ÐÂÐÍ¿¹HBV»¯ºÏÎïCMX157ÊÇÒ»ÖÖÀֳɵĿ¹²¡¶¾Ò©ÎïÌæÅµ¸£Î¤µÄ¸ßЧÀàËÆÎÏÖÔÚ´¦ÔÚHBV»¼ÕßµÄ2aÆÚÁÙ´²ÊÔÑéÖС£CMX157ÆäÐÂÐ͵ĸΰÐÏò·Ö×ӽṹ¿ÉÒÔµÖ´ïµÍˮƽµÄÌæÅµ¸£Î¤ÌåÄÚÑ»·£¬½µµÍÈ«Éí̻¶Ö鯽£¬´Ó¶øïÔÌÉö¸±×÷Óá£
¡øCMX157ÊÇ¿¹²¡¶¾Ò©ÎïÌæÅµ¸£Î¤µÄ¸ßЧÀàËÆÎï(ͼƬȪԴ£ºContraVir¹ÙÍø)
CMX157ÒÔǰÍê³ÉÁËÔÚ¿µ½¡×ÔÔ¸ÕßÖоÙÐеÄ1bÆÚ½×¶ÎµÄ¼ÁÁ¿µÝÔöÁÙ´²Ñо¿£¬ÆäÖÐÊÔÑé¼ÓÈëÕßÌìÌì½ÓÊÜÖÁ¶à100mgµÄ¼ÁÁ¿ÖÎÁÆ´ï14Ì죬ÏÔʾ³öÁËÓÅÒìµÄÇå¾²ÐÔ¡¢ÄÍÊÜÐÔºÍÒ©ÎïÂþÑܸſö¡£»ùÓÚCMX157ÁìÓò¼Ñ(best-in-class)µÄDZÁ¦£¬ContraVirÒÔΪCMX157¿ÉÒÔ³ÉΪÒÒÐ͸ÎÑ×ÍŽáÖÎÁÆÖеĻùʯÒòËØ¡£
ÉÏÊö2aÆÚ¶àÖØµÝÔö¼ÁÁ¿ÁÙ´²ÊÔÑé×ܹ²ÕÐļÁË60Ãû³õÖÎÂýÐÔHBVѬȾµÄ»¼Õߣ¬½«CMX157ÓëÏÖÓбê×¼ÖÎÁƼƻ®¾ÙÐÐÁËÁÆÐ§½ÏÁ¿¡£Ë³Ðò¼ÁÁ¿µÝÔöģʽÉè¼ÆÁËÿ×é10λ»¼Õߣ¬ÁƳÌÖÜΧ£¬»®·Ö½ÓÊÜÁË5¡¢10¡¢25¡¢50ºÍ100ºÁ¿ËµÄÖðÈÕÒ»´Î¼ÁÁ¿£¬¼ÓÉÏÿ×éÁ½Ãû½ÓÊÜ300mg¼ÁÁ¿±ê×¼ÖÎÁƼƻ®µÄ»¼Õß¡£
ÏÖÔÚ£¬½ÓÊÜ5ºÁ¿ËºÍ10ºÁ¿ËµÄС×éÊÔÑéÒѾ˳ËìÍê³É£¬Ðû²¼µÄÖÐÆÚÊý¾ÝÀ´×Ô10ÃûHBVѬȾ»¼Õߣ¬Íê³ÉÁË14ÌìÌìÌìÒ»´Î£¬¿Ú·þ25ºÁ¿ËCMX157£¬ÆäËûÁ½ÃûHBV»¼ÕßÒ²¿Ú·þ300mg±ê×¼ÖÎÁƼƻ®¼ÁÁ¿´ï14Ìì¡£Óë»ùÏßˮƽÏà±È£¬½ÓÊÜCMX157ÖÎÁƵϼÕßHBV²¡¶¾ÔØÁ¿Æ½¾ù½µµÍ¸ß´ï99%¡£Ö÷ÒªµÄÊÇ£¬CMX157µÄ¿¹²¡¶¾»îÐÔÓëÔÚ±ê×¼ÖÎÁƼƻ®µÄ¿¹²¡¶¾»îÐÔÏ൱£¬¿ÉÊǼÁÁ¿Ö»ÓÐ1/12¡£
¡øCMX157ÔÚ¶¯ÎïÄ£×ÓÖеÄÌåÄÚÂþÑÜ(ͼƬȪԴ£ºContraVir¹ÙÍø)
±¾Ñо¿µÄÒ»¸öÒªº¦Ä¿µÄÊǼà²âѪҺÖлîÐÔÌæÅµ¸£Î¤µÄˮƽ£¬ÆäÌåÄÚ̻¶Ö鯽ÊÇÔì³ÉÍѰи±×÷ÓõÄÒªº¦ÒòËØÖ®Ò»¡£¿Ú·þ¸øÒ©ºó£¬ÔÚÂýÐÔHBV»¼ÕßÒÔ¼°ÏÈǰµÄ¿µ½¡×ÔÔ¸ÕßÑо¿ÖУ¬ÑªÒºÖеÄCMX157ºÍ»îÐÔÌæÅµ¸£Î¤µÄˮƽÊÇ´óÖ³ɼÁÁ¿±ÈÀý¡£ÖµµÃ×¢ÖØµÄÊÇ£¬Óë·þÓñê×¼ÖÎÁƼƻ®µÄ»¼ÕßÏà±È£¬CMX157ËÆºõ½ûÖ¹Ò×ÔÚѪҺÖÐÆÊÎö³É»îÔ¾µÄÌæÅµ¸£Î¤¡£CMX157ÓÐÍûʵÏÖÀàËÆ¿¹²¡¶¾»îÐÔ£¬Í¬Ê±ÏÔÖø½µµÍÌåÄÚϵͳÐÔµÄÌæÅµ¸£Î¤Ì»Â¶Ö鯽¡£
ContraVirϯִÐйÙJames SapirsteinÏÈÉú˵µÀ£º¡°ÎÒÃǶÔÕâЩÁÙ´²Ð§¹û¸ÐÓ¦Ð˷ܺÍÐË·Ü£¬ÓÉÓÚËüÃÇ֤ʵCMX157¾ß±¸ÓÐÓÃÖÎÁÆHBVѬȾµÄÖØ´óDZÁ¦¡£µÍ¼ÁÁ¿µÄCMX157¿ÉÓÐÓýµµÍ²¡¶¾ÔØÁ¿£¬¼ÓÉÏÓÅÒìµÄÇå¾²ÐÔÑéÖ¤Á˸ÃÒ©ÎïÆæÒìµÄ¸Î°ÐÏò»úÖÆ£ºÌæÅµ¸£Î¤µÄ¿¹²¡¶¾»îÐÔ¼¯ÖÐÔÚ¸ÎÔàÖУ¬ÊµÏÖÁ˽ϵͼÁÁ¿ºÍСҩÎï̻¶ÏµĿ¹HBVÐ§Òæ¡£»ùÓÚÕâЩÕýÔÚ±¬·¢µÄÓÅÒìÊý¾Ý£¬ÎÒÃÇÒÔΪCMX157¾ßÓÐ×÷ΪÍŽáÖÎÁÆHBVѬȾ¼Æ»®ÖеÄÇå¾²¸ßЧ»ùʯÒòËØµÄÖØ´óDZÁ¦¡£¡±
²Î¿¼×ÊÁÏ£º
[1] ContraVir Release: CMX157 Demonstrates 99% Viral Load Reduction In Ongoing Head-To-Head Phase 2a Clinical Study Vs. Viread In Hepatitis B Patients
[2] CMX157 Demonstrates 99% Viral Load Reduction in Ongoing Head-to-Head Phase 2a Clinical Study Vs. Viread? in Hepatitis B Patients
[3] ContraVir Pharmaceuticals ¹Ù·½ÍøÕ¾
[4] ÒÒÐ͸ÎÑסª¡ªÌìÏÂÎÀÉú×éÖ¯

Ãö¹«Íø°²±¸ 35092602000113ºÅ